Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protectin...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Nephrology
2022-11-01
|
| Series: | Kidney Research and Clinical Practice |
| Subjects: | |
| Online Access: | http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf |
| _version_ | 1797980738488893440 |
|---|---|
| author | Anthony T. P. Chan Sydney C. W. Tang |
| author_facet | Anthony T. P. Chan Sydney C. W. Tang |
| author_sort | Anthony T. P. Chan |
| collection | DOAJ |
| description | Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition. |
| first_indexed | 2024-04-11T05:59:41Z |
| format | Article |
| id | doaj.art-5cc29bf33fd94eb2840ef30055cbdc4e |
| institution | Directory Open Access Journal |
| issn | 2211-9132 2211-9140 |
| language | English |
| last_indexed | 2024-04-11T05:59:41Z |
| publishDate | 2022-11-01 |
| publisher | The Korean Society of Nephrology |
| record_format | Article |
| series | Kidney Research and Clinical Practice |
| spelling | doaj.art-5cc29bf33fd94eb2840ef30055cbdc4e2022-12-22T04:41:47ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322211-91402022-11-0141668269810.23876/j.krcp.21.2856160Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitorsAnthony T. P. Chan0Sydney C. W. Tang1 Division of Nephrology, Department of Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China Division of Nephrology, Department of Medicine, Queen Mary Hospital, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, ChinaProgress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the management of DKD by lowering proteinuria and protecting organs, other novel treatment approaches with good evidence and efficacy that can be used in conjunction with a RAASi or SGLT2i in managing DKD have emerged in the past few years. This review discusses the evidence for glucagon-like peptide-1 receptor agonist, selective mineralocorticoid receptor antagonist, and selective endothelin A receptor antagonist, emerging treatment options for DKD beyond SGLT2 inhibition.http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdfdiabetic kidney diseasediabetic nephropathiesglucagon-like peptide-1 receptor agonistnon-steroidal mineralocorticoid receptor antagonistselective endothelin receptor antagonistsodium-glucose transporter 2 inhibitors |
| spellingShingle | Anthony T. P. Chan Sydney C. W. Tang Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors Kidney Research and Clinical Practice diabetic kidney disease diabetic nephropathies glucagon-like peptide-1 receptor agonist non-steroidal mineralocorticoid receptor antagonist selective endothelin receptor antagonist sodium-glucose transporter 2 inhibitors |
| title | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
| title_full | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
| title_fullStr | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
| title_full_unstemmed | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
| title_short | Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors |
| title_sort | advances in the management of diabetic kidney disease beyond sodium glucose co transporter 2 inhibitors |
| topic | diabetic kidney disease diabetic nephropathies glucagon-like peptide-1 receptor agonist non-steroidal mineralocorticoid receptor antagonist selective endothelin receptor antagonist sodium-glucose transporter 2 inhibitors |
| url | http://www.krcp-ksn.org/upload/pdf/j-krcp-21-285.pdf |
| work_keys_str_mv | AT anthonytpchan advancesinthemanagementofdiabetickidneydiseasebeyondsodiumglucosecotransporter2inhibitors AT sydneycwtang advancesinthemanagementofdiabetickidneydiseasebeyondsodiumglucosecotransporter2inhibitors |